PRESS RELEASE published on 07/23/2026 at 09:22, 1 month 20 days ago Inside Information / Other news releases ABL Diagnostics selected by the \u00c9vry Commercial Court to acquire TEXCELL's operations, enhancing life sciences and infectious diseases activities at Genopole Acquisition Molecular Diagnostics ABL Diagnostics Genopole TEXCELL
BRIEF published on 07/13/2026 at 08:05, 1 month 30 days ago Bilan Semestriel du Contrat de Liquidité d'ABL Diagnostics en 2026 Contrat De Liquidité Bilan Semestriel Transactions Boursières ABL Diagnostics Première Moitié 2026
BRIEF published on 07/13/2026 at 08:05, 1 month 30 days ago Half-yearly review of the ABL Diagnostics Liquidity Contract in 2026 Liquidity Contract Stock Market Transactions ABL Diagnostics Half-year Review First Half Of 2026
PRESS RELEASE published on 07/13/2026 at 08:00, 1 month 30 days ago Acquisition ou cession des actions de l'émetteur / Information relative au contrat de liquidité ABL Diagnostics publie son bilan semestriel du contrat de liquidité pour S1 2026, détaillant les transactions et ressources au 30/06/2026 Contrat De Liquidité Bilan Semestriel Transactions Ressources ABL Diagnostics
BRIEF published on 06/18/2026 at 13:57, 2 months 23 days ago ABL Diagnostics : Croissance et Perspectives pour 2026 Croissance Partenariats INVEST SECURITIES Diagnostic Moléculaire Génotypage
BRIEF published on 06/18/2026 at 13:57, 2 months 23 days ago ABL Diagnostics Projects Notable Growth and Upward Potential Strategic Partnerships Revenue Increase Buy Recommendation ABL Diagnostics Growth 2026
BRIEF published on 06/18/2026 at 13:57, 2 months 23 days ago ABL Diagnostics prévoit une croissance notable et un fort potentiel de développement. Partenariats Stratégiques Recommandation D'achat Augmentation Des Revenus Croissance 2026 Diagnostics ABL
BRIEF published on 06/18/2026 at 13:57, 2 months 23 days ago ABL Diagnostics: Growth and Outlook for 2026 INVEST SECURITIES Growth Partnerships Molecular Diagnosis Genotyping
PRESS RELEASE published on 06/18/2026 at 13:52, 2 months 23 days ago Inside Information / Other news releases ABL Diagnostics confirms growth trajectory with strong upside potential. Invest Securities raises target price to €8.7 and maintains 'Buy' recommendation INVEST SECURITIES Target Price Growth Trajectory Upside Potential ABL Diagnostics
PRESS RELEASE published on 06/18/2026 at 13:52, 2 months 23 days ago Informations privilégiées / Autres communiqués ABL Diagnostics confirme sa trajectoire de croissance avec un fort levier de revalorisation identifié. Recommandation d'achat avec objectif de cours à 8,7€ Croissance Recommandation D'achat Objectif De Cours Diagnostic Moléculaire ABL Diagnostics
Published on 09/12/2026 at 02:35, 11 hours ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 14 hours 35 minutes ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 15 hours 30 minutes ago Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 16 hours 10 minutes ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 20 hours 35 minutes ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 07:30, 6 hours 5 minutes ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 15 hours 20 minutes ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 15 hours 25 minutes ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 17 hours 51 minutes ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 19 hours 20 minutes ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 07:00, 1 day 6 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 6 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 18 hours ago Availability of the 2026 Interim Financial Report
